Background: Farletuzumab (FAR) is a humanized monoclonal antibody that binds to the folate receptor alpha, a potentially attractive target since it is over-expressed in EOC but is largely absent in normal epithelium. A Phase I dose escalation of FAR in platinum-resistant EOC showed no dose-limiting toxicities. A Phase II study of FAR with carboplatin and paclitaxel in platinum-sensitive EOC in first relapse showed a 93% patient benefit and 20% of second remissions were longer than first remission. In a recent Phase III study in relapsed platinum-sensitive EOC, the PLD/carboplatin combination showed superiority in progression free survival compared to carboplatin/paclitaxel. The current study is being conducted to assess the safety of FAR in combination with PLD/carboplatin in women with platinum-sensitive EOC in first or second relapse. Methods: A multicenter, single-arm study enrolled 15 subjects aged 47 to 82 with platinum-sensitive EOC in first or second relapse defined by either CA-125 or Response Evaluation Criteria In Solid Tumors (RECIST) criteria between July 2010 and January 2011 for treatment with weekly FAR 2.5mg/kg in combination with carboplatin AUC 4-5 and PLD 30mg/m² every 4 weeks for 6 cycles. Following 6 cycles of combination, maintenance treatment with weekly single agent FAR 2.5mg/kg continues until disease progression. The study’s primary objective is to assess the safety of FAR/carboplatin/PLD by standard assessment and grading using NCI CTCAEv3. Results: Preliminary safety data showed that patients tolerated treatment well. In one patient FAR administration was interrupted due to gastrointestinal toxicity. Two patients required delay in carboplatin/PLD administration due to neutropenia. Palmar-plantar erythrodysesthesia was observed in two subjects. No cardiac toxicity was appreciated with FAR/carboplatin/PLD treatment. No severe adverse events have been documented and all subject remain on study to date. Conclusions: These preliminary safety data indicate that combination of FAR, carboplatin and PLD is well tolerated. Complete safety profile will be assessed and final results will be presented.